Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody provides an update on the company’s plans for developing a novel therapy for patients with early-stage Dupuytren’s disease, “Our overall aim continues to be to develop new, patented uses for anti-tumor necrosis factor (‘TNF’) therapy for major unmet medical needs. To achieve this, we plan to: (1) Perform innovative ‘translational’ clinical research to improve medical care for important unmet medical needs; and (2) Execute on our business objectives to bring beneficial therapies to patients, and thus deliver value for our investors,” Dr. Woody writes. “Due to the determination, dedication and expertise of our consultant Prof. Jagdeep Nanchahal, who leads our clinical trials, we have been able to complete the first large-scale trial for early-stage Dupuytren’s disease, which was able to continue due to Prof. Nanchahal’s leadership, unlike many other trials that were closed due to the COVID-19 pandemic. Early-stage Dupuytren’s disease (‘DD’) affects millions of patients in the U.S. and Europe and for which there is currently no approved therapy. Importantly, there are no randomized, placebo-controlled trials to support other possible treatments, including the use of radiotherapy or corticosteroids. Therefore, at present, patients have to wait until their fingers are curled into the palm of the hand before being offered relief via surgery or collagenase, both of which have shortcomings, including the risk of recurrence of the disease.”

To view the full press release, visit https://ibn.fm/7r1FC

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company. The company is driving groundbreaking studies into clinical programs, which are seeking to develop treatments for major unmet clinical needs. The company’s primary platform is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.